A
Alan K. Burnett
Researcher at University of Glasgow
Publications - 46
Citations - 1244
Alan K. Burnett is an academic researcher from University of Glasgow. The author has contributed to research in topics: Myeloid leukemia & Acute promyelocytic leukemia. The author has an hindex of 15, co-authored 46 publications receiving 1041 citations. Previous affiliations of Alan K. Burnett include National Cancer Research Institute & Royal Hospital for Sick Children.
Papers
More filters
Journal ArticleDOI
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
Miguel A. Sanz,Miguel A. Sanz,Pierre Fenaux,Martin S. Tallman,Elihu H. Estey,Bob Löwenberg,Tomoki Naoe,Eva Lengfelder,Hartmut Döhner,Alan K. Burnett,Sai Juan Chen,Vikram Mathews,Harry J. Iland,Eduardo Magalhães Rego,Hagop M. Kantarjian,Lionel Adès,Giuseppe Avvisati,Pau Montesinos,Uwe Platzbecker,Farhad Ravandi,Nigel H. Russell,Francesco Lo-Coco +21 more
TL;DR: This review contains specific recommendations for the identification and management of the most important complications such as the bleeding disorder APL differentiation syndrome, QT prolongation, and other all-trans retinoic acid- and ATO-related toxicities.
Journal ArticleDOI
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients excluding acute promyelocytic leukemia from the UK MRC AML10 and 12 trials
Rosemary E. Gale,Robert Kerrin Hills,Robert Kerrin Hills,Panagiotis D. Kottaridis,Panagiotis D. Kottaridis,Sivatharsini Srirangan,Sivatharsini Srirangan,Keith Wheatley,Keith Wheatley,Alan K. Burnett,Alan K. Burnett,David C. Linch,David C. Linch +12 more
TL;DR: It is suggested that at present there is no strong evidence that FLT3 status should influence the decision to proceed to transplantation.
Journal ArticleDOI
Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia
Rosemary E. Gale,Robert Kerrin Hills,Arnold Pizzey,Panagiotis D. Kottaridis,D. Swirsky,Amanda F. Gilkes,E. Nugent,Ken I. Mills,Keith Wheatley,Ellen Solomon,Alan K. Burnett,David C. Linch,David Grimwade +12 more
TL;DR: In in vitro differentiation assays using primary APL blasts, the FLT3 inhibitor CEP-701 had a greater effect on cell survival/proliferation inFLT3/ITD+ cells, but this inhibition was reduced in the presence of ATRA.
Journal ArticleDOI
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial
TL;DR: It is indicated that FLA may be inferior to standard chemotherapy in high-risk AML and that the outcome is not improved with the addition of either G-CSF or ATRA.
Journal ArticleDOI
Haematological reconstitution following high dose and supralethal chemo-radiotherapy using stored, non-cryopreserved autologous bone marrow
TL;DR: Haematological reconstitution in these patients was acceptable but slower (greater than 1·0 × 109/l neutrophils between days 26 and 40; greater than 20 ×109/l platelets between days 23 and 77).